Clinical trial
Safety of Everolimus and Pemetrexed in Lung Cancer Patients
NCT00434174 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00434174 |
|---|---|
| Title | Safety of Everolimus and Pemetrexed in Lung Cancer Patients |
| Official title | A Phase I Study Investigating the Combination of Everolimus With Pemetrexed in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Non Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Everolimus, Pemetrexed |
| Enrollment | 48 |
| Start date | Dec 1, 2006 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Feb 13, 2007 |
| Last update posted | Dec 21, 2020 |
| Countries | Australia, Belgium, Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: